Arbutus Biopharma Corp Stock Beta

ABUS Stock

USD 3.30 0.02 0.60%

Arbutus Biopharma Corp fundamentals help investors to digest information that contributes to Arbutus Biopharma's financial success or failures. It also enables traders to predict the movement of Arbutus Stock. The fundamental analysis module provides a way to measure Arbutus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arbutus Biopharma stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Arbutus Biopharma Corp Company Beta Analysis

Arbutus Biopharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Beta

Covariance

Variance

More About Beta | All Equity Analysis

Current Arbutus Biopharma Beta

1.93

Most of Arbutus Biopharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arbutus Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Arbutus Beta Driver Correlations

Understanding the fundamental principles of building solid financial models for Arbutus Biopharma is extremely important. It helps to project a fair market value of Arbutus Stock properly, considering its historical fundamentals such as Beta. Since Arbutus Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arbutus Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arbutus Biopharma's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Tangible Assets	Accounts Payable	Long Term Debt	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Capital Surpluse	Accumulated Depreciation	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.72	-0.04	-0.09	0.1	0.97	0.72	-0.22	0.64	0.9	0.37	0.06	0.96	0.21	0.42	0.97	0.19	-0.15	0.02	-0.05	0.08	0.14	0.08	-0.05
Total Stockholder Equity	1.0		-0.74	-0.03	-0.09	0.08	0.95	0.72	-0.23	0.62	0.9	0.37	0.05	0.95	0.23	0.42	0.96	0.21	-0.17	0.0	-0.07	0.09	0.15	0.11	-0.07
Net Debt	-0.72	-0.74		-0.2	-0.06	0.38	-0.64	-0.52	0.24	-0.41	-0.64	0.02	0.29	-0.7	-0.33	-0.25	-0.68	0.15	0.23	0.19	0.25	-0.25	-0.19	-0.25	0.19
Retained Earnings	-0.04	-0.03	-0.2		-0.06	-0.83	-0.07	-0.56	0.09	0.29	-0.01	-0.78	-0.91	0.12	-0.38	-0.63	0.04	-0.57	-0.75	-0.95	-0.36	0.34	0.39	-0.22	-0.76
Net Receivables	-0.09	-0.09	-0.06	-0.06		-0.03	-0.07	0.02	0.04	-0.21	-0.08	-0.12	-0.17	-0.06	-0.02	-0.2	-0.07	-0.31	0.3	0.12	0.23	-0.13	-0.05	-0.03	0.23
Short Term Investments	0.1	0.08	0.38	-0.83	-0.03		0.15	0.53	-0.2	-0.08	0.13	0.81	0.86	-0.06	0.24	0.68	0.0	0.56	0.68	0.76	0.47	-0.48	-0.24	0.13	0.64
Total Liab	0.97	0.95	-0.64	-0.07	-0.07	0.15		0.7	-0.17	0.66	0.89	0.38	0.07	0.96	0.13	0.42	0.96	0.15	-0.09	0.05	-0.02	0.06	0.11	-0.01	0.0
Total Current Assets	0.72	0.72	-0.52	-0.56	0.02	0.53	0.7		-0.38	0.34	0.63	0.76	0.53	0.54	0.5	0.78	0.58	0.45	0.32	0.56	0.12	0.04	-0.03	0.26	0.39
Common Stock	-0.22	-0.23	0.24	0.09	0.04	-0.2	-0.17	-0.38		-0.25	-0.15	-0.22	-0.18	-0.13	-0.12	-0.41	-0.13	-0.16	-0.03	-0.11	0.0	0.0	0.1	0.01	-0.03
Short Term Debt	0.64	0.62	-0.41	0.29	-0.21	-0.08	0.66	0.34	-0.25		0.58	-0.1	-0.1	0.61	-0.23	0.15	0.6	0.17	-0.51	-0.38	-0.22	0.22	0.33	-0.08	-0.41
Net Tangible Assets	0.9	0.9	-0.64	-0.01	-0.08	0.13	0.89	0.63	-0.15	0.58		0.33	-0.04	0.88	0.26	0.39	0.87	-0.04	0.01	0.02	0.13	-0.13	0.44	0.29	0.13
Accounts Payable	0.37	0.37	0.02	-0.78	-0.12	0.81	0.38	0.76	-0.22	-0.1	0.33		0.76	0.22	0.47	0.67	0.28	0.49	0.54	0.81	0.33	-0.17	-0.2	0.27	0.65
Long Term Debt	0.06	0.05	0.29	-0.91	-0.17	0.86	0.07	0.53	-0.18	-0.1	-0.04	0.76		-0.13	0.27	0.63	-0.05	0.8	0.5	0.8	0.23	-0.23	-0.43	0.13	0.52
Deferred Long Term Liab	0.96	0.95	-0.7	0.12	-0.06	-0.06	0.96	0.54	-0.13	0.61	0.88	0.22	-0.13		0.03	0.27	0.99	0.0	-0.25	-0.13	-0.06	0.07	0.11	-0.03	-0.13
Long Term Investments	0.21	0.23	-0.33	-0.38	-0.02	0.24	0.13	0.5	-0.12	-0.23	0.26	0.47	0.27	0.03		0.34	0.05	0.06	0.48	0.41	-0.07	0.09	0.27	0.54	0.37
Short Long Term Debt	0.42	0.42	-0.25	-0.63	-0.2	0.68	0.42	0.78	-0.41	0.15	0.39	0.67	0.63	0.27	0.34		0.3	0.48	0.46	0.56	0.3	-0.31	-0.26	0.13	0.42
Intangible Assets	0.97	0.96	-0.68	0.04	-0.07	0.0	0.96	0.58	-0.13	0.6	0.87	0.28	-0.05	0.99	0.05	0.3		0.08	-0.21	-0.04	-0.04	0.06	0.07	-0.02	-0.08
Property Plant Equipment	0.19	0.21	0.15	-0.57	-0.31	0.56	0.15	0.45	-0.16	0.17	-0.04	0.49	0.8	0.0	0.06	0.48	0.08		0.05	0.44	0.01	0.04	-0.4	-0.09	0.06
Current Deferred Revenue	-0.15	-0.17	0.23	-0.75	0.3	0.68	-0.09	0.32	-0.03	-0.51	0.01	0.54	0.5	-0.25	0.48	0.46	-0.21	0.05		0.8	0.55	-0.56	-0.1	0.29	0.88
Capital Surpluse	0.02	0.0	0.19	-0.95	0.12	0.76	0.05	0.56	-0.11	-0.38	0.02	0.81	0.8	-0.13	0.41	0.56	-0.04	0.44	0.8		0.49	-0.31	-0.31	0.25	0.88
Accumulated Depreciation	-0.05	-0.07	0.25	-0.36	0.23	0.47	-0.02	0.12	0.0	-0.22	0.13	0.33	0.23	-0.06	-0.07	0.3	-0.04	0.01	0.55	0.49		-0.8	0.0	0.29	0.71
Long Term Debt Total	0.08	0.09	-0.25	0.34	-0.13	-0.48	0.06	0.04	0.0	0.22	-0.13	-0.17	-0.23	0.07	0.09	-0.31	0.06	0.04	-0.56	-0.31	-0.8		0.07	-0.31	-0.55
Net Invested Capital	0.14	0.15	-0.19	0.39	-0.05	-0.24	0.11	-0.03	0.1	0.33	0.44	-0.2	-0.43	0.11	0.27	-0.26	0.07	-0.4	-0.1	-0.31	0.0	0.07		0.49	-0.01
Net Working Capital	0.08	0.11	-0.25	-0.22	-0.03	0.13	-0.01	0.26	0.01	-0.08	0.29	0.27	0.13	-0.03	0.54	0.13	-0.02	-0.09	0.29	0.25	0.29	-0.31	0.49		0.44
Capital Stock	-0.05	-0.07	0.19	-0.76	0.23	0.64	0.0	0.39	-0.03	-0.41	0.13	0.65	0.52	-0.13	0.37	0.42	-0.08	0.06	0.88	0.88	0.71	-0.55	-0.01	0.44

Click cells to compare fundamentals

In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Competition

Predict Arbutus Biopharma

In accordance with the recently published financial statements, Arbutus Biopharma Corp has a Beta of 1.926. This is 123.95% higher than that of the Biotechnology sector and 38.56% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

Arbutus Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arbutus Biopharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics of similar companies.

Arbutus Biopharma is currently under evaluation in beta category among its peers.

Arbutus Biopharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Arbutus Biopharma from analyzing Arbutus Biopharma's financial statements. These drivers represent accounts that assess Arbutus Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arbutus Biopharma's important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	269.2M	413.3M	351.7M	414.9M	373.4M	392.1M
Enterprise Value	219.9M	306.6M	323.1M	397.3M	357.6M	375.5M

Arbutus Biopharma ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arbutus Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arbutus Biopharma's managers, analysts, and investors.

Environmental

Governance

Social

Arbutus Biopharma Institutional Holders

Institutional Holdings refers to the ownership stake in Arbutus Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arbutus Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arbutus Biopharma's value.

		Shares
Advisor Group Holdings, Inc.	2024-12-31	1.4 M
Northern Trust Corp	2024-12-31	1.3 M
Fourworld Capital Management Llc	2024-12-31	1.2 M
Charles Schwab Investment Management Inc	2024-12-31	1.2 M
Hudson Bay Capital Management Lp	2024-12-31	1.1 M
Woodline Partners Lp	2024-12-31	971.6 K
Jpmorgan Chase & Co	2024-12-31	896.3 K
Saba Capital Management, Lp	2024-12-31	888 K
Corbin Capital Partners Lp	2024-12-31	682.5 K
Morgan Stanley - Brokerage Accounts	2024-12-31	22.6 M
Whitefort Capital Management, Lp.	2024-12-31	13.2 M

As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Arbutus Biopharma will likely underperform.

Arbutus Fundamentals

	Return On Equity	-0.68
	Return On Asset	-0.33
	Operating Margin	(13.05) %
	Current Valuation	498.97 M
	Shares Outstanding	189.49 M
	Shares Owned By Insiders	22.25 %
	Shares Owned By Institutions	55.33 %
	Number Of Shares Shorted	7.21 M
	Price To Earning	(1.16) X
	Price To Book	5.85 X
	Price To Sales	92.75 X
	Revenue	18.14 M
	Gross Profit	(56.05 M)
	EBITDA	(70.99 M)
	Net Income	(72.85 M)
	Cash And Equivalents	150.2 M
	Cash Per Share	1.00 X
	Total Debt	8.72 M
	Debt To Equity	0.02 %
	Current Ratio	5.29 X
	Book Value Per Share	0.56 X
	Cash Flow From Operations	(85.94 M)
	Short Ratio	9.95 X
	Earnings Per Share	(0.43) X
	Target Price	5.18
	Number Of Employees	73
	Beta	1.93
	Market Capitalization	625.32 M
	Total Asset	144.4 M
	Retained Earnings	(1.28 B)
	Working Capital	109.54 M
	Current Asset	183.88 M
	Current Liabilities	10.58 M
	Net Asset	144.4 M

About Arbutus Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arbutus Stock Analysis

When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC